Monday, October 22, 2018

Makis Papataxiarchis

President PhRMA Innovation Forum (PIF), Chairman, AMCHAM Pharma Committee

Makis Papataxiarchis
Makis Papataxiarchis

Makis Papataxiarchis has 20 years of experience in the Pharmaceutical sector and a 17-year old career at Johnson & Johnson. Since joining the company in 2000, he has held several senior roles such as Business Unit Director and Marketing & Sales Director.

In 2010 he moved to Romania as Janssen and Johnson & Johnson Managing Director. During his tenure in Romania was President of the National Association of Pharmaceutical Companies (ARPIM).

In 2013 he moved to the USA where he was appointed as National Director, Systems of Care, at Janssen Pharmaceuticals Inc. By the end of 2015, Mr. Papataxiarchis returns to his homeland as CEO of Janssen Pharmaceutical Companies of Johnson & Johnson for Greece, Cyprus and Malta. He is also President of PhRMA Innovation Forum (PIF) and Chairman of AMCHAM’s Pharma Committee.

He holds a Pharmacy degree, Master and PhD in Pharmaceuticals and Economics, as well as an MBA in Marketing Management.

International Speakers

Michael Drummond Mike Drummond is Professor of Health Economics and was Director of the Centre from December 1995 to September 2005. His particular field of interest is in the economic evaluation of health care treatments and programmes.
Dr Panos Kanavos Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health.
Katarzyna Kolasa, PhD Katarzyna Kolasa has more than 16 years of working experience in the healthcare sector, with 10 years with the pharmaceutical and medical devices industry and six with the public payer.
Vladimir Zah Vladimir Zah, PhD(c), brings 20+ years of Health Economics technology and business experience. Since 2000, in various roles as Health Economist, Project Manager and Chief Investigator, Vlad has implemented more than 170 health economic models and assessments in the phase 2, 3 and 4 settings, across various disease areas for top 20 global pharmaceutical companies; work supported with over 50 publications.

© 2018 Boussias Communications, all rights reserved., T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team